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QExcision of anomalous muscle bundles as an important
addition to extended septal myectomy for treatment of left
ventricular outflow tract obstructionShuiyun Wang, MD,a Hao Cui, MD,a Qinjun Yu, MD,b Haibo Chen, MD,a Changsheng Zhu, MD,a
Jingjin Wang, MD,c Minghu Xiao, MD,c Yanbo Zhang, MD,d Rong Wu, MD,a and Shengshou Hu, MDaABSTRACT
Objective: This study aims to report our preliminary experience and anatomic
findings in the surgical treatment and postoperative management of hypertrophic
obstructive cardiomyopathy.
Methods: This study included 277 patients with hypertrophic obstructive cardio-
myopathy (168 [60.65%] were male), with a median age of 47 years (interquartile
range, 35-54 years), who underwent surgical myectomy performed by 1 surgeon
in Fuwai Hospital between May 2010 and April 2015. The median follow-up was
14 months (interquartile range, 7-24 months).
Results:A total of 127 patients (45.85%) underwent concomitant procedures, and 2
patients (0.72%) died in the early perioperative days. The left ventricular outflow
gradient decreased from 78 mm Hg (interquartile range, 61-100 mm Hg) to
11 mm Hg (interquartile range, 8-15 mm Hg) when discharged (P<.001). Of the
228 patients with well-documented anatomic description, more than 80% had
various intraventricular anomalies. The cumulative survivalwas 99.28% (95% con-
fidence interval, 97.15-99.82) at 1 year and 96.98% (95% confidence interval,
92.56-98.79) at 5 years. Of the surviving 272 patients, 268 (98.53%) were catego-
rized with functional class I and II of the New York Heart Association classification
at the latest evaluation.
Conclusions: Anomalous muscle bundles are common in hypertrophic obstructive
cardiomyopathy, and they may lead to middle-apical obstruction. Surgical myec-
tomy provides excellent clinical outcomes with low risk for sufficient relief of
obstruction and radical correction of intraventricular anomalies in patients with hy-
pertrophic obstructive cardiomyopathy. (J ThoracCardiovasc Surg 2016;152:461-8)From the Departments of aCardiovascular Surgery, bAnesthesiology, and cEchocar-
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The Journal of Thoracic and Cardiovascular SurA whole piece of surgical specimen with anomalous
muscle bundles. The weight of the largest piece
was 13.6 g, and the total was 17.5 g.iCentral Message
This study proves the favorable outcome of
myectomy for HOCM and reports the details
of classified intraventricular anomalies.Perspective
Anomalous muscle bundles may be the leading
cause of middle-apical obstruction in patients
without evident septal hypertrophy. They may
extend surgery indications for patients with
middle-apical obstruction of the left ventricular
outflow tract in the future. We hope this will
draw some attention to the relationship between
arrhythmia and anomalous muscle bundles in
HCM.See Editorial Commentary page 469.Hypertrophic cardiomyopathy (HCM) is a prevalent cardiac
disease inherited as an autosomal dominant trait. HCMaffects 1 in 500 of the total population1,2 and is the most
common cause of sudden cardiac death (SCD) in young
individuals.3,4 The clinical phenotype of HCM varies
from an asymptomatic state to severe heart failure
complicated by SCD. Abnormal ventricular septal
thickness, a characteristic pathologic phenotype of
HCM, may lead to left ventricular outflow tract
(LVOT) obstruction. Medication currently is the first-line
therapy for the treatment of hypertrophic obstructiveQR code will take
cle title page.
gery c Volume 152, Number 2 461
Abbreviations and Acronyms
APM ¼ anterior papillary muscle
CABG ¼ coronary artery bypass grafting
HCM ¼ hypertrophic cardiomyopathy
HOCM ¼ hypertrophic obstructive cardiomyopathy
ICD ¼ implantable cardioverter defibrillator
IQR ¼ interquartile range
IVS ¼ interventricular septum
LVOT ¼ left ventricular outflow tract
NYHA ¼ New York Heart Association
PPM ¼ posterior papillary muscle
proBNP ¼ pro-B-type natriuretic peptide
SAM ¼ systolic anterior motion
SCD ¼ sudden cardiac death
TTE ¼ transthoracic echocardiography
VSD ¼ ventricular septal defect
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Qcardiomyopathy (HOCM). Nevertheless, relief of LVOT
obstruction by invasive methods is unavoidable for patients
with severe symptoms and refractory to maximum medical
therapies. Recent guidelines have recommended that surgi-
cal septal myectomy is the gold standard for the treatment of
HOCM.5,6
Septal myectomy, also known as the ‘‘extended Morrow
procedure,’’ has evolved into a comprehensive repair
technique for LVOT obstruction and abnormalities of the
mitral apparatus over the past decades.7 Extension of the
myectomy area and correction of mitral apparatus
anomalies have considerably improved the surgical effect
of this treatment. However, the anomalous intraventricular
anatomy has not been fully revealed. Over the past several
years, we have performed an extended septal myectomy
in more than 250 patients with HOCM and identified a
high prevalence of associated intraventricular anomalies.
Compared with previous myectomy series in Fuwai
Hospital,8 surgical reconstruction of the LVOT addressing
these anomalies significantly improved the postoperative
effect. In this article, we report our experience regarding
the surgical treatment of HOCM.
MATERIALS AND METHODS
Patients
This study included 277 patients with HOCM who underwent septal
myectomy by 1 surgeon (SW) at the Fuwai Hospital from May 2010 to
April 2015. Indications of surgery included the following: (1) an LVOT
pressure gradient of 50 mm Hg or greater at rest or with physiologic
provocation (mainly physiologic exercise), as determined under Doppler
transthoracic echocardiography (TTE); and (2) presence of severe limiting
symptoms refractory to maximum pharmacologic therapy. Meanwhile,
patients who met the following criteria were not recommended to undergo
operation: (1) aged more than 70 years, because we lack experience with
these patients; and (2) the presence of an additional risk for on-pump
cardiac surgery, which may lead to early postoperative death. The study
was approved by The Ethics Committee of Fuwai Hospital, and all patients
signed informed consent.462 The Journal of Thoracic and Cardiovascular SurgPerioperative Evaluation
Preoperative and postoperative TTE were performed to determine
pressure gradient, ventricular septal thickness, mitral valve anomalies,
and other necessary data. To guide intraoperative myectomy, we
successively measured the septal thickness of the point 15 mm, 25 mm,
35 mm, and 45 mm under the right coronary sinus nadir. The point
25 mm under the right coronary sinus nadir was taken as a landmark
point to represent the septal thickness. Intraoperative transesophageal
echocardiography was conducted to guide the operation and report the
real-time effect of the surgery. All patients underwent coronary
angiography or coronary computed tomography angiography before the
operation. Concomitant coronary artery bypass grafting (CABG) was
performed when necessary. Preoperative and postoperative electro-
cardiography was conducted to detect heart block and other severe
electrophysiologic disorders.
Surgical procedures. As described in our previous report,9 we used
an extended septal myectomy, which evolved from the traditional Morrow
procedure. The patient was put in the reverse Trendelenburg and left lateral
prone position. After a median incision with sternotomy, cardiopulmonary
bypass was performed using ascending aortic cannulation and venae cava
cannulation. The aorta was transected approximately 7 mm above the right
coronary ostium. The left-right sinus and right nonsinus commissures were
elevated and retracted with 5-0 Prolene suture. Auxiliary light and loupe
magnification were used to achieve better inspection of the left ventricular
cavity. The resection ranges were as follows: The upper end was located at
approximately 4 mm below the aortic ring; the lower end was extended to
the apex of the left ventricle; from the right side, the myectomy was started
slightly rightward to the nadir of the right aortic cusp; and to the left,
resection was terminated near the mitral anterior commissure. Elongated
leaflets were not routinely folded, unless severe regurgitation or systolic
anterior motion (SAM) remained after resection. To obtain amore posterior
position, partial excision of the papillary muscles off the left ventricular
wall was necessary. Aberrant muscle bundles were resected, including
aberrant muscle bundles located around the root of papillary muscles,
between the apex and the left ventricular free wall, and between the
papillary muscles and the free wall. In most cases, all anomalous chordae
tendineae and muscle bundles were removed, and aberrant adhesions were
detached. However, chordae and thin muscle bundles connecting anterior
commissure and adjacent septum should be reserved if they exist.
Secondary chordae that linked to the region of mitral leaflets near the
ring were cut. After resections were completed, the bases of the papillary
muscles should be seen by looking through the incision of the aortic
root. Then, the LVOT and mitral valve were carefully and thoroughly
reexplored. All inspection, exploration, and resection were carried out
via a transaortic approach. Mitral repair or replacement was performed
when necessary. According to preoperative examination and intraoperative
exploration results, tricuspid repair, CABG, atrial fibrillation radiofre-
quency ablation, and other procedures were conducted appropriately. We
routinely used bipolar clamp via biatrial access in atrial fibrillation
ablation. Auricular appendectomy and amputation of the Marshall
ligament were simultaneously performed with ablation. After weaning
from cardiopulmonary bypass, immediate reoperation was performed if
intraoperative transesophageal echocardiography detected a postoperative
LVOT gradient of 30 mm Hg or greater. To avoid reinitiation of
cardiopulmonary bypass, we have the following intraoperative strategies:
(1) create a smooth and plane septumwith a touch-feeling of approximately
10 mm thickness; (2) release the papillary muscles to the apex; and
(3) perform an intraoperative saline injection leak test in patients with
preoperative moderate to severe concentric mitral regurgitation.
Statistics
Perioperative data were collected during the patients’ hospital stay, and
follow-up data were obtained by telephone questionnaire. Basic follow-up
information included survival status, heart function, incidence of adverseery c August 2016
FIGURE 1. Awhole piece of surgical specimen with anomalous muscle
bundles. The weight of the largest piece was 13.6 g, and the total was
17.5 g.
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Qevents, postoperative treatment, and follow-up examinations. Nine patients
(3.25%) were temporarily lost to the cross-sectional follow-up; for these
patients, we used the results of the last follow-up. The follow-up end point
was all-cause mortality. Normally distributed data were provided as
mean  standard deviation and compared with Student t test. Continuous
variables with skewed distributions were expressed as median
(interquartile range [IQR]) and compared with Wilcoxon signed-rank test
(related samples) or Mann–Whitney U test (independent samples).
Categoric data were compared by using the chi-square test. All reported
probability values were 2-tailed. SPSS 22.0 Statistical Software (SPSS
Inc, Chicago, Ill) and Prism GraphPad 5.0 (GraphPad Software Inc,
La Jolla, Calif) were used for calculations and illustrations.
RESULTS
Baseline Characteristics
The baseline characteristics of the cohort are shown in
Table 1. Patients in this group had a median age of 47 years
(IQR, 35-54) during the operation. A total of 168 patients
were male, and 19 patients in the cohort were aged 16 years
or less. The median body weight was 68 kg (IQR, 57-77),
and the median height was 166 cm (IQR, 158-172). All
patients received beta-blocker or calcium channel blocker
treatment before the operation. Most patients manifested
severe limiting symptoms, such as dyspnea and stethalgia.
Seven patients had previously undergone alcohol ablation,
52 patients had confirmed family history of HCM, and
38 patients had a family history of sudden death.
Anatomic Features
We recorded detailed anatomic features in the later 228
patients after we gradually recognized the intraventricular
anomalies. The median weight of the operation specimens
was 6.84 g (IQR, 5.18-9.26). Most of the 228 patients
had anomalous muscle bundles or chordae tendineae. ATABLE 1. Baseline characteristics
Characteristic Median value or number (n ¼ 277)
Age (y) 47 (IQR, 35-54)
Male 168 (60.65%)
Body weight (kg) 68 (IQR, 57-77)
Height (cm) 166 (IQR, 158-172)
Heart rate (beats/min) 76 (IQR, 70-80)
Blood pressure (mm Hg) 115 (IQR, 108-120)/70 (IQR, 65-80)
Preoperative symptoms






Calcium blocker 171 (61.73%)
Previous alcohol ablation 7 (2.53%)
Confirmed family history of HCM 52 (18.77%)
Family history of sudden death 38 (13.72%)
ICD implantation 0 (0%)
IQR, Interquartile range; HCM, hypertrophic cardiomyopathy; ICD, implantable
cardioverter defibrillator.
The Journal of Thoracic and Carepresentative specimen with anomalous muscle bundles
or chordae tendineae is shown in Figure 1. The anomalies
observed generally were divided into 4 types: (1) anoma-
lous muscle bundles (Figure 2, A1-A3) between the
interventricular septum (IVS) and other myocardial parts,
including the ventricular apex, anterior papillary muscle
(APM), and posterior papillary muscle (PPM); (2) APM
or PPM adhesion to the IVS and left ventricular wall; (3)
accessory muscles that originated from the APM
(Figure 2, B1-B3), PPM (Figure 2, C1-C3), or IVS were
directly inserted into leaflets; and (4) anomalous tendinous
chordae linkage to IVS. As shown in Table 2, the most
shared anomaly was aberrant muscle bundles between the
ventricular apex and the IVS, which occurred in
approximately three quarters of the patients. More than
one half of the patients had anomalous muscle bundles
connecting IVS and papillary muscles. Thirty-five patients
presented adhesion to the IVS of papillary muscles or their
fusion. Abnormal linkage with tendinous chordae was
another commonly seen anomaly and detected in 101
patients. Further analysis showed that adhesion and
anomalous muscular linkage more frequently occurred in
bodies of papillary muscles than in head parts, whereas
tendinous chordae linkage exhibited the opposite trend. In
addition, excrescent muscle bundles in the apical ventricle
area were detected in most patients, all of whom underwent
resection. In some patients, the septum was covered with
thick fibrous membrane, and thus case dissection was
performed.Concomitant Procedures
After thorough preoperative assessment and careful
intraoperative investigation, 150 patients (aged 44 years
[IQR, 33-53]) underwent isolated myectomy, and 127 pa-
tients underwent concomitant procedures (Table 3). Mainrdiovascular Surgery c Volume 152, Number 2 463
FIGURE 2. Anomalous muscle bundles. A1-A3, Surgical specimen with anomalous muscle bundles. B1-B3, Accessory APM (white arrow) directly
inserted into A1 leaflet. C1-C3, Abnormal PPM (white arrow) directly inserted into A3 leaflet.
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Qconcomitant procedures were CABG in 47 patients (aged
47 years [IQR, 37-55]); tricuspid valvuloplasty in 42
patients (aged 51 years [IQR, 44-64]); mitral valvuloplasty
or mitral valve replacement in 59 patients (aged 51 years
[IQR, 46-61]); and radiofrequency ablation-modified
maze procedure in 18 patients (aged 50 years [IQR,
44-57]). A total of 23 patients underwent double-orifice
mitral repair; 10 patients underwent prosthetic ring
implantation; 8 patients underwent double-orifice plus pros-
thetic ring implantation; 3 patients underwent quadrangular464 The Journal of Thoracic and Cardiovascular Surgresection plus prosthetic valve ring implantation; and 1
patient underwent double-orifice repair, quadrangular
resection, and prosthetic valve ring implantation. Mitral
replacements mainly were related to irreparable lesions,
including subacute bacterial endocarditis in 8 patients and
severe mitral valve calcification in 6 patients. A total of
43 patients had coronary myocardial bridge detected by
angiography or computed tomography angiography.
Among the patients who underwent CABG, 22 were related
to the coronary myocardial bridge in the left anteriorery c August 2016
TABLE 2. Main anatomic anomalies
Anomalies type Number (%), n ¼ 228
Anomalous muscular bundles between IVS and
Ventricular apex 178 (78.1%)
APM 116 (50.9%)
PPM 27 (11.8%)
Adhesion to IVS or LV free wall
APM 27 (11.8%)
PPM 16 (7.0%)
Accessory muscle inserted to leaflet
From IVS 5 (2.2%)
From APM 11 (4.8%)
From PPM 1 (0.4%)
Anomalous tendinous chordae linkage to IVS
APM 57 (25.0%)
PPM 71 (31.1%)
One patient may have had more than 1 anomaly. IVS, Interventricular septum;
APM, anterior papillary muscle; PPM, posterior papillary muscle; LV, left ventricle.
Wang et al Acquired: Hypertrophic Cardiomyopathy
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Qdescending branch and 25 were ascribed to coronary
atherosclerosis. Only 1 patient with myocardial bridge in
the posterior descending artery had myocardial bridge
unroofing. In most patients who underwent CABG because
of a myocardial bridge, we used the left internal thoracic
artery as a graft. The blood flow rate of most grafted left
internal thoracic arteries was 15 to 20 mL/min. Compared
with those in the isolated myectomy group, patients whoTABLE 3. Frequencies of concomitant procedures and early results
Parameter
Median value or
number (n ¼ 277)
Procedures







Maze procedure 18 (6.50%)
RVOTO correction 3 (1.08%)
Paracardiac pheochromocytoma resection 1 (0.36%)
Ventricular aneurysm plication 1 (0.36%)
WPW pathway amputation 3 (1.08%)
Coronary myocardial bridge unroofing 1 (0.36%)
Ascending aorta replacement 1 (0.36%)
VSD closure 4 (1.44%)
In-hospital death 2 (0.72%)
Duration of cardiopulmonary bypass (min) 121 (IQR, 102-160)
Duration of aortic crossclamping (min) 85 (IQR, 67-109)
Duration of postoperative ventilation (h) 17 (IQR, 14-21)
Postoperative hospital stay (d) 8 (IQR, 7-11)
CABG, Coronary artery bypass grafting; TVP, tricuspid valvuloplasty; MVP, mitral
valvuloplasty; MVR, mitral valve replacement; AVR, aortic valve replacement; AVP,
aortic valvuloplasty;RVOTO, right ventricular outflow tract obstruction;WPW, Wolf–
Parkinson–White; VSD, ventricular septal defect.
The Journal of Thoracic and Casimultaneously underwent mitral operation (P < .001),
tricuspid valvuloplasty (P < .001), and maze operation
(P ¼ .028) were older. The cardiopulmonary bypass and
aortic crossclamping times of the whole cohort were
121 minutes (IQR, 102-160) and 85 minutes (IQR,
67-109), respectively. Compared with patients who
underwent isolated myectomy, patients who underwent
concomitant operation presented significantly increased
cardiopulmonary bypass time (153 minutes [IQR,
122-205] vs 106 minutes [IQR, 92-122], P< .001) and
aortic crossclamping time (106 minutes [IQR, 89-141] vs
68 minutes [IQR, 59-82], P<.001).
Early Results
Two patients died early after the operation. A 60-year-old
woman, who had previously undergone alcohol ablation,
manifested intraoperative ventricular septal perforation
because of the rupture of necrotic septal tissues. Another
59-year-old woman died of intractable postoperative low
cardiac output, even though extracorporeal membrane
oxygenation therapy was conducted. Iatrogenic ventricular
septal defect (VSD) occurred in 4 patients, and closure with
a patch via a right atrium approach was performed. One
patient underwent aortic valve replacement, and 2 patients
underwent aortic valvuloplasty because of iatrogenic aortic
valve injury. Of the 6 patients who had preoperative right
bundle branch block, only the first 3 relied on pacemaker
and the remaining 3 patients had normal sinus rhythm
postoperatively. A total of 6 patients received pacemaker
implantation early after the operation. The postoperative
ventilation time and postoperative hospital stay of the
remaining patients were 17 hours (IQR, 14-21) and 8 days
(IQR, 7-11), respectively. Concomitant operation also
increased ventilation time (17 hours [IQR, 16-25] vs
17 hours [IQR, 13-18], P ¼ .019) and postoperative
in-hospital days (9 days [IQR, 7-13] vs 7 days [IQR, 7-9],
P<.001).
Before discharge, the remaining 275 patients underwent
careful TTE reexamination. In comparison with those
from preoperative TTE, LVOT pressure gradient decreased
to 11 mm Hg (IQR, 8-15 mm Hg) from 78 mm Hg (IQR,
61-100 mm Hg), and SAM was eliminated in almost all
patients, except for 2 with persistent mild SAM. Mitral
regurgitation also was considerably alleviated. As shown
in Table 4, left atrial diameter, ventricular septal thickness,
left ventricular end-diastolic diameter, left ventricular
ejection fraction, and right ventricular diameter were
significantly decreased. In the last 2 years, we evaluated
preoperative pro-B-type natriuretic peptide (proBNP) levels
in 136 patients. The preoperative median value was
1676 pg/mL (IQR, 848-2874). At the latest follow-up, 43
patients provided their postoperative proBNP level at least
3 months after the operation. Postoperative proBNP level
(647 pg/mL [IQR, 266-1080]) significantly decreasedrdiovascular Surgery c Volume 152, Number 2 465
TABLE 4. Parameters of preoperative transthoracic echocar-




Left atrial diameter (mm) 44 (IQR, 40-49) 39 (IQR, 34-43) <.001
Ventricular septal thickness
(mm)
19 (IQR, 16-22) 14 (IQR, 12-16) <.001
Left ventricular end-diastolic
diameter (mm)
42 (IQR, 38-46) 44 (IQR, 40-48) <.001
Left ventricular ejection
fraction (%)
73 (IQR, 68-78) 65 (IQR, 60-70) <.001
Right ventricular diameter
(mm)
20 (IQR, 18-22) 18 (IQR, 17-20) <.001
Main pulmonary artery
diameter (mm)
24 (IQR, 22-26) 23 (IQR, 21-26)
LVOT pressure gradient
(mm Hg)
78 (IQR, 61-100) 11 (IQR, 8-15) <.001







IQR, Interquartile range; LVOT, left ventricular outflow tract; SAM, systolic anterior
motion.
FIGURE 3. Kaplan–Meier survival chart. The cumulative survival curve
of the total cohort. Red shaded area indicates 95% confidence interval.
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Qcompared with preoperative proBNP (1610 pg/mL [IQR,
748-2431], P<.001).Middle-Term Results
At the latest follow-up (14 months [IQR, 7-24]), most of
the patients were in acceptable physical state. Two male
patients aged 15 and 14 years died of suspected sudden
cardiac arrest 15 and 16 months after the operation,
respectively. The former had syncope (once) and a septal
thickness of 36 mm preoperatively, and the latter had a
septal thickness of 31 mm and terminated the use of
beta-blocker medication after the operation without
consulting a physician. Both patients underwent isolated
myectomy and denied a family history of HCM and SCD.
A 66-year-old male patient died of lung cancer 16 months
after the operation. All 3 patients had LVOT pressure
gradients less than 15 mmHg at the latest TTE examination
and were categorized in New York Heart Association
(NYHA) heart function class I when they died. The
cumulative survival probability was 99.28% at 1 year and
96.98% at 5 years (Figure 3). Of the remaining 272 patients,
268 were classified in NYHA class I and II and 4 were
classified in NYHA III and IV, and these 4 patients were
aged more than 60 years. Another 2 patients underwent
pacemaker implantation in the later days. No patients had
accepted implantable cardioverter defibrillator (ICD)
implantation, although some of them had urgent needs for
SCD prevention therapy.466 The Journal of Thoracic and Cardiovascular SurgDISCUSSION
We began to explore surgical treatment for HOCM in
2000 and started to routinely use the extended Morrow
operation in 2010.8-10 Our previous retrospective report
proved the favorable short-term outcome of myectomy in
Chinese patients.9 To our knowledge, the present study
contains the largest cohort among studies reported in
Asia. However, we excluded patients aged more than
70 years. In geriatric patients, especially in elderly female
patients, the ventricular septum is more fragile and brings
more risk of iatrogenic VSD. Moreover, according to the
study by Maron and colleagues,11 patients with HCM
surviving into the seventh decade of life are at low risk
for disease-related morbidity and mortality.
HOCM has been thought to be primarily induced by
hypertrophic septal bulge in LVOT and has been the
theoretic basis for alcohol ablation, which aimed to collapse
the septal bulge by postinfarction cicatricial contraction.
Primary septal myectomy mainly resected the bulge part
of the hypertrophic septum. With advancements in surgery,
various intraventricular anomalies were discovered, and
most of them were related to mitral apparatus.12,13 Many
procedures, including valve plication, papillary muscle
repositioning, and secondary chordae cutting, have been
reported to address mitral anomalies.14-16 Gruner and
colleagues17 reported that left ventricular apical-basal
muscle bundles were detected by cardiac magnetic
resonance imaging in 63% of patients with HCM. In the
present study, we report a large amount of data on detailed
intraventricular anomalies that were directly observed by
the operator. Consistent with previous reports, our finding
indicates that HCM has both myocardial dysfunction and
intraventricular dysplasia. HCM is more than a kind of
cardiomyopathy. The apex-IVS muscle bundles may lead
to middle-LVOT or apical obstruction, whereas mitral
apparatus–related anomalies participate in mitral SAM
and regurgitation. Resection of IVS-apex muscle bundlesery c August 2016
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Qenlarged the volume of middle and apical ventricles, which
may restore the function of the apical ventricle and
increase cardiac output. A study from Mayo Clinic
suggested that surgical myectomy decreased the risk for
lethal arrhythmias despite the mean resting gradient of
only 17.4  25 mm Hg in the control group.18 This result
indicates that relief of LVOT obstruction is not the only
reason for myectomy-induced decrease in SCD incidence.
The unconfirmed contributory factors may include the
removal of anomalous muscles, considering that papillary
muscles contain abundant Purkinje fibers and are an
important origin of ventricular arrhythmias. However,
further investigations are necessary to uncover the
relationship between anomalous muscle bundles and
SCD. We believe that adequate length of septal excision
is extremely important to surgical effect. It has been
reported that an inadequate length of septal excision was
the most common cause of recurrent LVOTobstruction after
myectomy.19 We used long-handled forceps and scalpels to
ensure an adequate length of resection. Intraoperative
measurement of LVOT gradient could assist the surgeon
in defining the extent of myectomy.20
Approximately half of the patients in the present cohort
underwent concomitant procedures. In most cases, mitral
dysfunction disappeared after extended myectomy,
including removal of anomalous muscle bundles and
tendinous chordae. However, for mitral valves with other
structural lesions and pathologic changes, especially in
patients aged more than 60 years, additional mitral repair
should be performed. If the lesion or anomaly is irreparable
or mitral repair greatly increases cardiopulmonary bypass
time, mitral replacement should be immediately performed.
Coronary disease is another common concomitant
cardiomyopathy of HCM and leads to poor long-term
prognosis.21,22 Coronary myocardial bridge was detected
in approximately 15% of the patients in the present
cohort, and the proportion was lower than that reported
from a study in Canada.23 Because unroofing has been
proven safe with satisfactory pleasurable short-term
outcomes,24 we are shifting to unroofing therapy for
appropriate patients.
Left bundle branch block, iatrogenic VSD, and aortic
valve injury are the main complications of transaortic septal
myectomy. In the present cohort, pacemaker implantation
incidence (2.90%) was satisfactory. This incidence was
attributed to the adoption of conservative surgical strategies
in patients with preoperative right bundle branch block,
although it led to a slightly higher residual gradient of up
to 20 mm Hg in some patients. However, we believe that
avoiding pacemaker implantation could result in additional
benefits to long-term outcomes and quality of life,
especially in young patients. In principle, aortic valve injury
and iatrogenic VSD were prone to occur in young
patients with small aortic roots and old patients with anThe Journal of Thoracic and CaIVS thickness of approximately 18 mm, respectively. A
recent study also suggested that prior alcohol septal ablation
was related to worse outcomes after myectomy.25 However,
another study suggested that alcohol septal ablation did not
independently affect outcomes.26 Patients with HOCMmay
obtain increased benefits in experienced heart centers,
where cardiologists could have close communication with
experienced surgeons and provide the patients with
reasonable advice about alcohol ablation treatment.
Progressive heart failure and SCD are the 2 main
disastrous outcomes of HCM. HCM-related heart failure
can be prevented or delayed by medication after the
operation, and few patients may need heart transplantation.
As the most common cause of SCD in young population,
HCM induces SCD mainly by fatal ventricular arrhythmia,
which could be converted by ICD.27 HCM-induced SCD is
widely related to multiple factors.5,6 Surgical myectomy
aimed to relieve LVOT obstruction was proven to reduce
the incidence of appropriate ICD discharge and risk for
SCD.18 Nevertheless, treatment of young patients with
obstructive HCM remains challenging for physicians in at
least 2 aspects. First, surgical operation on a growing heart
offers extra difficulties because of poor exposure and
limited operating space via the aorta. Furthermore, patients
undergoing myectomy at a younger age are supposed to
have rapid progression of disease and extra SCD risk.
Therefore, postoperative medication and SCD prevention
may be important for young patients. However, the high
cost of ICD and low consultation rates place SCD
prevention in an awkward position in China.
In recent years, septal myectomy has developed into a
comprehensive repair of anomalous LVOT. Similar to the
results from North America and Europe,23,28-32 our study
proved that myectomy performed in experienced centers
is a safe and effective strategy for medication-refractory
patients with obstructive HCM. Short- and medium-term
outcomes are satisfying. Moreover, consistent with
previous reports,28,30 concomitant operations do not
greatly increase additional lethal risk. An experienced
team consisting of fixed members may be a key factor to
safety.
Study Limitations
The present study, limited by the short follow-up, could
not demonstrate the long-term improvement. Recurrent
valvular insufficiency and LVOT obstruction were not
clearly determined. Anatomic description was highly
dependent on intraoperative inspection, and it needed
systemic imaging and pathologic studies. The lack of an
appropriate control group and complete follow-up
examinations also limited further analyzing the role of
intraventricular anomalies. Deficiency of necessary
preoperative examinations, such as cardiac magnetic
resonance imaging, was another important limitation. Therdiovascular Surgery c Volume 152, Number 2 467
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Qretrospective and single-operator design might have
incurred selection bias.
In conclusion, extended septal myectomy is effective and
safe for patients with HOCM. Intraventricular anomalies
are common in these patients. Excision of anomalous
muscle bundles should be an important addition to septal
myectomy.Conflict of Interest Statement
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